Logotype for AlzChem Group AG

AlzChem Group (ACT) Q4 2024 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for AlzChem Group AG

Q4 2024 earnings summary

2 Dec, 2025

Executive summary

  • Achieved record sales of EUR 554 million in 2024, up 3% year-over-year, with specialty chemicals driving growth and now representing 63% of total sales and nearly 90% of earnings contribution.

  • EBITDA reached EUR 105.3 million, a 29% increase year-over-year, surpassing the EUR 100 million milestone; net income hit a record EUR 54.2 million, up 56%.

  • Dividend proposal of EUR 1.80 per share, a 50% increase, with a payout ratio expected to remain at the lower end of 30-35% due to ongoing CapEx needs.

  • Received a platinum EcoVadis rating for sustainable corporate governance, placing in the top 1% for ESG, and published a comprehensive CSRD-compliant non-financial report.

  • Major investment project of approximately EUR 140 million underway for Nitroguanidine expansion, with construction starting in Germany and US site search ongoing.

Financial highlights

  • Specialty chemicals segment sales grew 9% to nearly EUR 350 million, with EBITDA up 28% to EUR 94 million and margin rising to 27%.

  • Group EBITDA margin improved to 19% from 15.1% last year.

  • Earnings per share increased to EUR 5.31 from EUR 3.40.

  • Operating cash flow rose 45% to EUR 105 million; net financial position shifted from EUR 46 million net debt to EUR 12.9 million net assets.

  • Equity increased to EUR 207 million, equity ratio at 43%; cash and cash equivalents rose to EUR 61.5 million.

Outlook and guidance

  • 2025 sales expected to reach EUR 580 million (+5%), EBITDA to EUR 113 million (+7%), driven by further volume growth in specialty chemicals, especially Creapure, Creamino, and Nitroguanidine.

  • Custom manufacturing volumes and prices anticipated to recover as destocking effects subside and order intake improves.

  • CapEx for 2025 projected at around EUR 100 million, before EU subsidies.

  • Free cash flow expected to remain positive in 2025, supported by customer prepayments for nitroguanidine expansion.

  • Assumes stable global economy, high electricity prices, and no major geopolitical disruptions.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more